These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 16307706)

  • 1. A review of entecavir in the treatment of chronic hepatitis B infection.
    Rivkin A
    Curr Med Res Opin; 2005 Nov; 21(11):1845-56. PubMed ID: 16307706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection.
    Sims KA; Woodland AM
    Pharmacotherapy; 2006 Dec; 26(12):1745-57. PubMed ID: 17125436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Entecavir for chronic hepatitis B: a review.
    Palumbo E
    Ther Drug Monit; 2008 Feb; 30(1):1-4. PubMed ID: 18223455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.
    Lai CL; Rosmawati M; Lao J; Van Vlierberghe H; Anderson FH; Thomas N; Dehertogh D
    Gastroenterology; 2002 Dec; 123(6):1831-8. PubMed ID: 12454840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entecavir: a new nucleoside analogue for the treatment of chronic hepatitis B.
    Rivkin A
    Drugs Today (Barc); 2007 Apr; 43(4):201-20. PubMed ID: 17460784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic hepatitis B: a wider range of therapeutic options.
    Prescrire Int; 2007 Aug; 16(90):157-62. PubMed ID: 17724844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Entecavir for the treatment of chronic hepatitis B virus infection.
    Matthews SJ
    Clin Ther; 2006 Feb; 28(2):184-203. PubMed ID: 16678641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entecavir: new drug. Chronic hepatitis B: a last resort.
    Prescrire Int; 2007 Oct; 16(91):183-5. PubMed ID: 17926822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
    Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
    Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients.
    Cheng PN; Chang TT
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):569-79. PubMed ID: 18847396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Entecavir for the treatment of chronic hepatitis B infection.
    Shepherd J; Gospodarevskaya E; Frampton G; Cooper K
    Health Technol Assess; 2009 Oct; 13 Suppl 3():31-6. PubMed ID: 19846026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current therapy with nucleoside/nucleotide analogs for patients with chronic hepatitis B.
    Xu XW; Chen YG
    Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):350-9. PubMed ID: 16911930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Chang TT; Chao YC; Gorbakov VV; Han KH; Gish RG; de Man R; Cheinquer H; Bessone F; Brett-Smith H; Tamez R
    J Viral Hepat; 2009 Nov; 16(11):784-9. PubMed ID: 19457141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels.
    Wong DK; Yuen MF; Ngai VW; Fung J; Lai CL
    Antivir Ther; 2006; 11(7):909-16. PubMed ID: 17302253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entecavir: a new treatment option for chronic hepatitis B.
    Zoulim F
    J Clin Virol; 2006 May; 36(1):8-12. PubMed ID: 16515882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic hepatitis B--treatment with nucleoside analogues.
    Leung N
    Med J Malaysia; 2005 Jul; 60 Suppl B():22-7. PubMed ID: 16108169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.
    Chang TT; Gish RG; Hadziyannis SJ; Cianciara J; Rizzetto M; Schiff ER; Pastore G; Bacon BR; Poynard T; Joshi S; Klesczewski KS; Thiry A; Rose RE; Colonno RJ; Hindes RG;
    Gastroenterology; 2005 Oct; 129(4):1198-209. PubMed ID: 16230074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
    Sherman M; Yurdaydin C; Sollano J; Silva M; Liaw YF; Cianciara J; Boron-Kaczmarska A; Martin P; Goodman Z; Colonno R; Cross A; Denisky G; Kreter B; Hindes R;
    Gastroenterology; 2006 Jun; 130(7):2039-49. PubMed ID: 16762627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of chronic hepatitis B].
    Marcellin P; Asselah T; Boyer N
    Rev Prat; 2005 Mar; 55(6):624-32. PubMed ID: 15913114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.